Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485593 | 0.91 | CNR2 (0.40) | KDRCNR2CNR1EGLN1RIPK2 | |
| SCHEMBL21481855 | 0.89 | CNR2 (0.51) | CNR2CNR1MCHR1CHRM1 | |
| SCHEMBL21481779 | 0.89 | CNR2 (0.42) | CNR2CNR1CSNK2A2CSNK2A1RIPK2 | |
| SCHEMBL21506548 | 0.88 | HSD11B1 (0.41) | CNR2CNR1EGLN1BMPR1BBMPR1A | |
| SCHEMBL21481774 | 0.86 | CNR1 (0.43) | CNR2CNR1MCHR1 | |
| SCHEMBL26620644 | 0.86 | CYP3A4 (0.39) | KDRCNR2CNR1CSNK2A2CSNK2A1 | |
| SCHEMBL21481825 | 0.86 | CNR2 (0.47) | CNR2CNR1EGLN1MCHR1CHRM1 | |
| SCHEMBL21482092 | 0.86 | NAAA (0.43) | CNR2CNR1MCHR1PDE5A | |
| SCHEMBL21481677 | 0.85 | CNR2 (0.41) | CNR2CNR1EGLN1 | |
| SCHEMBL31203690 | 0.85 | CNR2 (0.36) | KDRCNR2CNR1EGLN1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | KDR 2571/4885CNR2 3/4885CNR1 6/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | KDR 2571/4885CNR2 3/4885CNR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.